Determinants of quality life of patients with psoriasis treated with biologics

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15120%2F20%3A73603042" target="_blank" >RIV/61989592:15120/20:73603042 - isvavai.cz</a>

Výsledek na webu

<a href="https://kont.zsf.jcu.cz/artkey/knt-202004-0012_determinanty-kvality-zivota-pacientov-so-psoriazou-na-biologickej-liecbe.php" target="_blank" >https://kont.zsf.jcu.cz/artkey/knt-202004-0012_determinanty-kvality-zivota-pacientov-so-psoriazou-na-biologickej-liecbe.php</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.32725/kont.2020.039" target="_blank" >10.32725/kont.2020.039</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Determinants of quality life of patients with psoriasis treated with biologics

Popis výsledku v původním jazyce

Aim: The aim of the study was to assess the quality life of patients with psoriasis treated with biologics, and to analyze the various factors that determine it. Methods: The cross-sectional study was realized with 117 patients at the Centre for Biologic Therapy in Slovakia. The factors analyzed were: Dermatology Life Quality Index (DLQI), The Brief Illness Perception Questionnaire (BIPQ), General Anxiety Disorder-7 (GAD-7), Psoriasis Area Severity Index (PASI), localization of skin changes, duration of the disease, length of use of biologics, BMI. Results: Mean score of DLQI was 9.03 (SD = 6.59, range = 2-23). DLQI significantly correlates with PASI (r = 0.347), length of use of biologics (r = -0.286), illness perception (r = 0.557) and anxiety (r = 0.338). Hierarchical regression analysis showed that PASI (β = 0.252) and illness perception (β = 2.209) were significant predictors of a patient&apos;s quality life. Conclusions: The findings of study indicate that the quality life of psoriatic patients treated with biologics is determined by the disease severity and illness perception. Therefore it is very important to include a psychosocial dimension (assessment, effective intervention) in the care of these patients.

Název v anglickém jazyce

Determinants of quality life of patients with psoriasis treated with biologics

Popis výsledku anglicky

Aim: The aim of the study was to assess the quality life of patients with psoriasis treated with biologics, and to analyze the various factors that determine it. Methods: The cross-sectional study was realized with 117 patients at the Centre for Biologic Therapy in Slovakia. The factors analyzed were: Dermatology Life Quality Index (DLQI), The Brief Illness Perception Questionnaire (BIPQ), General Anxiety Disorder-7 (GAD-7), Psoriasis Area Severity Index (PASI), localization of skin changes, duration of the disease, length of use of biologics, BMI. Results: Mean score of DLQI was 9.03 (SD = 6.59, range = 2-23). DLQI significantly correlates with PASI (r = 0.347), length of use of biologics (r = -0.286), illness perception (r = 0.557) and anxiety (r = 0.338). Hierarchical regression analysis showed that PASI (β = 0.252) and illness perception (β = 2.209) were significant predictors of a patient&apos;s quality life. Conclusions: The findings of study indicate that the quality life of psoriatic patients treated with biologics is determined by the disease severity and illness perception. Therefore it is very important to include a psychosocial dimension (assessment, effective intervention) in the care of these patients.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30307 - Nursing

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Kontakt

ISSN

1212-4117

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

285-290

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85098084366